ZA201806849B - Acetyl¿leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function - Google Patents
Acetyl¿leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionInfo
- Publication number
- ZA201806849B ZA201806849B ZA2018/06849A ZA201806849A ZA201806849B ZA 201806849 B ZA201806849 B ZA 201806849B ZA 2018/06849 A ZA2018/06849 A ZA 2018/06849A ZA 201806849 A ZA201806849 A ZA 201806849A ZA 201806849 B ZA201806849 B ZA 201806849B
- Authority
- ZA
- South Africa
- Prior art keywords
- leucine
- acetyl
- pharmaceutically acceptable
- acceptable salt
- cognitive function
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606834 | 2016-04-19 | ||
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201806849B true ZA201806849B (en) | 2019-07-31 |
Family
ID=58633040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/06849A ZA201806849B (en) | 2016-04-19 | 2018-10-15 | Acetyl¿leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10905670B2 (https=) |
| EP (2) | EP3445351B1 (https=) |
| JP (3) | JP7387264B2 (https=) |
| KR (4) | KR102632670B1 (https=) |
| CN (2) | CN118593463A (https=) |
| AU (2) | AU2017252507B2 (https=) |
| BR (1) | BR112018071547A2 (https=) |
| CA (1) | CA3021155A1 (https=) |
| DK (1) | DK3445351T3 (https=) |
| ES (1) | ES2994242T3 (https=) |
| FI (1) | FI3445351T3 (https=) |
| HR (1) | HRP20241552T1 (https=) |
| HU (1) | HUE069219T2 (https=) |
| IL (3) | IL262379B (https=) |
| LT (1) | LT3445351T (https=) |
| MD (1) | MD3445351T2 (https=) |
| MX (2) | MX388461B (https=) |
| PL (1) | PL3445351T3 (https=) |
| PT (1) | PT3445351T (https=) |
| RS (1) | RS66142B1 (https=) |
| RU (1) | RU2745912C2 (https=) |
| SG (2) | SG11201809031XA (https=) |
| SI (1) | SI3445351T1 (https=) |
| SM (1) | SMT202400459T1 (https=) |
| WO (1) | WO2017182802A1 (https=) |
| ZA (1) | ZA201806849B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2994242T3 (en) * | 2016-04-19 | 2025-02-05 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility |
| WO2018029658A1 (en) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| EP3886986A1 (en) | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Deuterated analogs of acetyl-leucine |
| SMT202400334T1 (it) * | 2019-03-02 | 2024-09-16 | Intrabio Ltd | (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche |
| US20250099355A1 (en) * | 2023-07-18 | 2025-03-27 | Sytheon Ltd | Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| WO2008134844A1 (en) * | 2007-05-08 | 2008-11-13 | Multi Formulations Ltd. | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| WO2011025518A1 (en) * | 2009-08-27 | 2011-03-03 | Albert Einstein College Of Medicine Of Yeshiva University | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| ES2994242T3 (en) * | 2016-04-19 | 2025-02-05 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility |
| US12458614B2 (en) * | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 ES ES17719692T patent/ES2994242T3/es active Active
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 MX MX2018012739A patent/MX388461B/es unknown
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en not_active Ceased
- 2017-04-19 PT PT177196920T patent/PT3445351T/pt unknown
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active Active
- 2017-04-19 LT LTEPPCT/GB2017/051090T patent/LT3445351T/lt unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active Active
- 2017-04-19 RS RS20241222A patent/RS66142B1/sr unknown
- 2017-04-19 SM SM20240459T patent/SMT202400459T1/it unknown
- 2017-04-19 PL PL17719692.0T patent/PL3445351T3/pl unknown
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020247003393A patent/KR102791288B1/ko active Active
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 FI FIEP17719692.0T patent/FI3445351T3/fi active
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 MD MDE20190248T patent/MD3445351T2/ro unknown
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 EP EP24205813.9A patent/EP4501406A3/en active Pending
- 2017-04-19 HR HRP20241552TT patent/HRP20241552T1/hr unknown
- 2017-04-19 HU HUE17719692A patent/HUE069219T2/hu unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 SI SI201731566T patent/SI3445351T1/sl unknown
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active Ceased
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 DK DK17719692.0T patent/DK3445351T3/da active
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en not_active Abandoned
-
2023
- 2023-07-10 US US18/349,221 patent/US12329733B2/en active Active
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
-
2025
- 2025-05-13 US US19/206,473 patent/US20250332133A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2572126B (en) | Pharmaceutical | |
| GB2569961B (en) | Pharmaceutical | |
| ZA201806849B (en) | Acetyl¿leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function | |
| GB2572125B (en) | Pharmaceutical | |
| SG11201609405VA (en) | Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof | |
| SG11202012447YA (en) | Rapamycin analogs and uses thereof | |
| EP3638658C0 (en) | PHARMACEUTICAL COMPOUNDS | |
| GB201704965D0 (en) | Pharmaceutical compounds | |
| GB201703881D0 (en) | Pharmaceutical compounds | |
| ZA201904241B (en) | Novel compound and pharmacologically acceptable salt thereof | |
| IL272385A (en) | Drug compound and methods of preparation | |
| SG11201705759SA (en) | Cytotoxic hexim1 peptides and uses thereof | |
| IL267937A (en) | Amide compounds and their use | |
| IL269239A (en) | A pharmaceutical combination containing fonsimod | |
| IL276323A (en) | 4-Methyldihydropyrimidinone compounds and their pharmaceutical use | |
| IL283273A (en) | Pharmacy practices | |
| PT3438118T (pt) | Derivado de peptídeo e utilização deste | |
| IL271741A (en) | Peptide meters drug with improved pharmaceutical properties | |
| GB201702051D0 (en) | New Pharmaceutical use | |
| GB201608175D0 (en) | A composition for the detection of a drug | |
| GB201700867D0 (en) | Pharmaceutical compounds |